Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)

Taysha Gene Therapies has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $5.5 million for Q3 2025.

• Current Deferred Revenue for Q3 2025 came in at $5.5 million, down 53.52% year-over-year; the trailing twelve-month figure through Sep 2025 was $5.5 million (down 53.52% YoY), and the FY2024 annual result was $9.8 million, down 46.02% from the prior year.
• Current Deferred Revenue came in at $5.5 million for Q3 2025 at Taysha Gene Therapies, roughly flat from $5.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $33.6 million in Q4 2022 to a low of $5.5 million in Q2 2025.
• The 4-year median for Current Deferred Revenue is $14.1 million (2024), against an average of $15.7 million.
• Across the five-year window, Current Deferred Revenue sank 32.76% in 2024 and tumbled 59.62% in 2025, its largest moves.
• Taysha Gene Therapies' Current Deferred Revenue stood at $33.6 million in 2022, then slumped by 46.04% to $18.1 million in 2023, then slumped by 46.02% to $9.8 million in 2024, then sank by 43.88% to $5.5 million in 2025.
• The last three Current Deferred Revenue figures came in at $5.5 million (Q3 2025), $5.5 million (Q2 2025), and $7.5 million (Q1 2025), per Business Quant data.